Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?

Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Sep 18, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts

Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $7.06, signifying a +1% move from its prior day's close.

Zacks Investment Research • Sep 16, 2026

Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data

BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab supports biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data. Ginkgo Datapoints will provide discovery data generation services, including small mol.

Business Wire • Sep 16, 2026

Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines

BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it has been awarded a subcontract for up to $17.5M under the Advanced Research Projects Agency for Health's (ARPA-H) Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. Ginkgo will serve as a subcontractor to prime contractor Waterfall Scientific, Inc. on ESCALATOR (Engineering a Small-scale, Continuous-flow manufacturing Apparatus to Launch A Transformational Overhaul for RNA medicines), a mul.

Business Wire • Sep 10, 2026

Ginkgo Bioworks Q2 Earnings Call Highlights

Ginkgo Bioworks NYSE: DNA reported second-quarter 2026 revenue of $20 million, down 48% from the year-earlier period, as the company continued to shift its focus toward autonomous laboratory systems, contract research services and related software.

MarketBeat • Aug 8, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery

New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification BOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™ , a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific  and Inductive Bio . ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management.

PRNewsWire • May 26, 2026

Ginkgo Bioworks: Another Lost Year

Ginkgo Bioworks (DNA) reported Q1 revenues of $19.5M, down nearly 50% year-over-year and badly missing street estimates even after Biosecurity adjustments. Management is pivoting to autonomous labs but refuses to provide revenue guidance, causing analyst estimates to fall further. DNA continues to burn significant cash, with Q1 cash burn at $49M and 2026 guidance of $125M–$150M, leaving $373M in cash and no debt but weakening flexibility.

Seeking Alpha • May 13, 2026

Ginkgo Bioworks Q1 Earnings Call Highlights

Ginkgo Bioworks NYSE: DNA said it is sharpening its 2026 focus on autonomous laboratories after completing the divestiture of its biosecurity business and reporting lower year-over-year cash burn in the first quarter.

MarketBeat • May 10, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2026 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026